Cell-Free DNA for the Management of Classical Hodgkin Lymphoma

Camus, Vincent; Jardin, Fabrice

doi:10.3390/ph14030207

Cited by 14 publications

(16 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it can monitor the quality of response detecting the minimal residual disease, or the recurrence of the disease. These new biomarkers should be considered among the future predictive features, considering the improving technology and the emerging results, even though the requirement of validation in prospective analyses in childhood cHL [17][18][19].…”

Section: Discussionmentioning

confidence: 99%

Outcome of Children and Adolescents with Recurrent Classical Hodgkin Lymphoma: The Italian Experience

Garaventa

Parodi

Guerrini

et al. 2022

Cancers

View full text Add to dashboard Cite

The objective of this study was to identify prognostic factors for children and adolescents with relapsed or progressive classical Hodgkin’s lymphoma (cHL) to design salvage therapy tailored to them. We analyzed a homogeneous pediatric population, diagnosed with progressive/relapsed cHL previously enrolled in two subsequent protocols of the Italian Association of Pediatric Hematology and Oncology in the period 1996–2016. There were 272 eligible patients, 17.5% of treated patients with cHL. Overall survival (OS) and event-free survival (EFS) after a 10-year follow-up were 65.3% and 53.3%, respectively. Patients with progressive disease (PD), advanced stage at recurrence, and ≥5 involved sites showed a significantly worse OS. PD, advanced stage, and extra-nodal involvement at recurrence were significantly associated with a poorer EFS. Multivariable analysis identified three categories for OS based on the type of recurrence and number of localizations: PD and ≥5 sites: OS 34%; PD and <5 sites: OS 56.5%; relapses: OS 73.6%. Four categories were obtained for EFS based on the type of recurrence and stage: PD and stage 3–4: EFS 25.5%; PD and stage 1–2: EFS 43%; relapse and stage 3–4: EFS 55.4%; relapse and stage 1–2: EFS 72.1%. Patients with PD, in advanced stage, or with ≥5 involved sites had a very poor survival and they should be considered refractory to first- and second-line standard chemotherapy. Probably, they should be considered for more innovative approaches since the first progression. Conversely, patients who relapsed later with localized disease had a better prognosis, and they could be considered for a conservative approach.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcome of Children and Adolescents with Recurrent Classical Hodgkin Lymphoma: The Italian Experience

Garaventa

Parodi

Guerrini

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Lymphomas are the most common hematologic malignancies, and the gold standard for their diagnosis is tissue or lymph node biopsies, with a pathological examination after surgical resection or lymph node puncture; however, these are invasive examinations (sometimes, as in CNS (central nervous system) lymphoma, the sample may be not accessible) and a biopsy is not useful for monitoring the disease [ 89 ]. It is a heterogenous group of neoplasms, with significant differences in the treatment schemes, and non-Hodgkin lymphoma is the most frequent type [ 90 ].…”

Section: Lymphoid Malignanciesmentioning

confidence: 99%

“…Hodgkin lymphoma (HL) represents 10% of newly diagnosed lymphomas; the standard initial treatment is chemotherapy and/or radiotherapy, with a five-year progression-free survival rate of 65–90% [ 89 , 131 ]. Studies have been conducted in the attempt to detect peripheral blood mutations in cfDNA using NGS, finding that XPO1 E571K, ATM, KMT2D , and TP53 are frequently mutated in HL [ 132 , 133 ].…”

Section: Lymphoid Malignanciesmentioning

confidence: 99%

The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies

Colmenares

Álvarez

Barrio

et al. 2022

Cancers

View full text Add to dashboard Cite

The study of cell-free DNA (cfDNA) and other peripheral blood components (known as “liquid biopsies”) is promising, and has been investigated especially in solid tumors. Nevertheless, it is increasingly showing a greater utility in the diagnosis, prognosis, and response to treatment of hematological malignancies; in the future, it could prevent invasive techniques, such as bone marrow (BM) biopsies. Most of the studies about this topic have focused on B-cell lymphoid malignancies; some of them have shown that cfDNA can be used as a novel way for the diagnosis and minimal residual monitoring of B-cell lymphomas, using techniques such as next-generation sequencing (NGS). In myelodysplastic syndromes, multiple myeloma, or chronic lymphocytic leukemia, liquid biopsies may allow for an interesting genomic representation of the tumor clones affecting different lesions (spatial heterogeneity). In acute leukemias, it can be helpful in the monitoring of the early treatment response and the prediction of treatment failure. In chronic lymphocytic leukemia, the evaluation of cfDNA permits the definition of clonal evolution and drug resistance in real time. However, there are limitations, such as the difficulty in obtaining sufficient circulating tumor DNA for achieving a high sensitivity to assess the minimal residual disease, or the lack of standardization of the method, and clinical studies, to confirm its prognostic impact. This review focuses on the clinical applications of cfDNA on the minimal residual disease in hematological malignancies.

show abstract

“…Lymphomas are the most common hematologic malignancies, and the gold standard for their diagnosis is tissue or lymph node biopsy, with pathological examination after surgical resection or lymph node puncture; however, these are invasive examinations (sometimes, as in CNS (central nervous system) lymphoma, the sample may be not accessible) and a biopsy is not useful for monitoring the disease [92]. It is a heterogenous group of neoplasms, with significant differences in the treatment schemes, and non-Hodgkin lymphoma is the most frequent type [93].…”

Section: Lymphomas and Chronic Lymphocytic Leukemia (Table 7)mentioning

confidence: 99%

“…Hodgkin lymphoma (HL) represents 10% of newly diagnosed lymphomas; the standard initial treatment is chemotherapy and/or radiotherapy, with a five-year progressionfree survival rate of 65%-90% [134,92]. Studies have been conducted in the attempt to detect peripheral blood mutations in cfDNA using NGS, finding that XPO1 E571K, ATM, KMT2D, and TP53 are frequently mutated in HL [ 135,136].…”

Section: Hodgkin Lymphomamentioning

confidence: 99%

Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies

Colmenares¹,

Álvarez²,

Barrio³

et al. 2022

Preprint

View full text Add to dashboard Cite

The study of cell-free DNA (cfDNA) and other peripheral blood components (known as “liquid biopsies”) is promising and has been investigated especially in solid tumors. Nevertheless, it is increasingly showing greater utility in the diagnosis, prognosis, and response to treatment of hematological malignancies; in the future, it could prevent invasive techniques, such as bone marrow (BM) biopsy. Most of the studies about this topic have been focused on B cell lymphoid malignancies; some of them have shown that cfDNA can be used as a novel way for diagnosis and minimal residual monitoring in B cell lymphomas, using techniques such as next-generation sequencing (NGS). In myelodysplastic syndromes, multiple myeloma, or chronic lymphocytic leukemia, liquid biopsies may allow for an interesting genomic representation of the tumor clones affecting different lesions (spatial heterogeneity). In acute leukemias, it can be helpful in the monitoring of early treatment response and the prediction of treatment failure. In chronic lymphocytic leukemia, the evaluation of cfDNA permits the definition of clonal evolution and drug resistance in real-time. However, there are limitations such as the difficulty in obtaining sufficient circulating tumor DNA for achieving a high sensitivity to assess minimal residual disease or the lack of standardization of the method and clinical studies to confirm its prognostic impact. This review focuses on clinical applications of cfDNA on minimal residual disease in hematological malignancies.

show abstract

Cell-Free DNA for the Management of Classical Hodgkin Lymphoma

Cited by 14 publications

References 99 publications

Outcome of Children and Adolescents with Recurrent Classical Hodgkin Lymphoma: The Italian Experience

Outcome of Children and Adolescents with Recurrent Classical Hodgkin Lymphoma: The Italian Experience

The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies

Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies

Contact Info

Product

Resources

About